Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of TAK-861 in narcolepsy type 1
jRCT2031230135Recruiting
- Sponsor
- Takeda
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Primary endpoint: Number of participants with at least one treatment-emergent adverse event. Started Apr 2023; status: recruiting.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on jRCT2031230135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230135.